In a recent trial by Johnson & Johnson involving 45,000 volunteers, the efficacy of their single-dose, adenoviral-vectored, Ad26
In a recent trial by Johnson & Johnson involving 45,000 volunteers, the efficacy of their single-dose, adenoviral-vectored, Ad26.COV2.S vaccine in conferring protection against moderate to severe COVID-19 was 72% in…